In Q1 2026, NovoCure Ltd demonstrated continued revenue momentum with $174.1 million, despite a net loss of $71.1 million, supported by a strong liquidity position and a healthy current ratio of 2.9. Key regulatory and clinical advancements including positive PANOVA-4 Phase 2 trial data and recent FDA approvals reinforce the commercial appeal of its TTFields technology in challenging cancers such as pancreatic and non-small cell lung cancer. While the company benefits from a differentiated cancer therapy with limited direct competition, risks remain centered on regulatory hurdles, reimbursement complexities, and execution in international markets. Upcoming trial readouts and approval milestones remain crucial near-term catalysts.